Press Releases | Vertex Pharmaceuticals Newsroom

Date	Title	Additional Format
Oct 31, 2005	Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations Cambridge, MA, October 31, 2005 - Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that N. Anthony Coles, M.D., has resigned his position with the Company	Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations
Oct 26, 2005	Vertex Pharmaceuticals Reports Third Quarter 2005 Financial Results - VX-950 Phase Ib Combination Study Initiated - - Target Enrollment in VX-702 Phase II Rheumatoid Arthritis Study Achieved -	Vertex Pharmaceuticals Reports Third Quarter 2005 Financial Results
Oct 04, 2005	Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis Cambridge, MA, October 4, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it will concentrate its development investment in 2006 on	Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis
Oct 03, 2005	New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track Montreal, Canada, October 3, 2005 - New data show that patients with genotype 1 hepatitis C virus (HCV) infection treated with VX-950, an investigational oral HCV	New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track
Sep 09, 2005	Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated	Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock
Aug 09, 2005	Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated	Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock
Jul 27, 2005	Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results Cambridge, MA, July 27, 2005 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three months ended June 30, 2005. “Vertex’s progress in the second quarter of 2005 was	Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results
Jul 26, 2005	Study Results Presented on Pharmacokinetics of Once-Daily HIV Combination Therapy - Combination of Lexiva/r and Truvada Evaluated -	Study Results Presented on Pharmacokinetics of Once-Daily HIV Combination Therapy
Jul 26, 2005	Long-Term Safety Data of Lexiva/r in HIV Patients Co-Infected with Hepatitis - Combination of Lexiva/r and Truvada Evaluated -	Long-Term Safety Data of Lexiva/r in HIV Patients Co-Infected with Hepatitis
Jul 19, 2005	FDA Grants Fast Track Status for the Investigational HIV Protease Inhibitor 640385 (VX-385) - GlaxoSmithKline To Initiate Phase IIb Clinical Trial in HIV-infected Patients -	FDA Grants Fast Track Status for the Investigational HIV Protease Inhibitor 640385 (VX-385)
Jun 17, 2005	Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 Whitehouse Station, NJ and Cambridge, MA, June 17, 2005 - Merck & Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of an additional Phase I	Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680
Jun 15, 2005	Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters Cambridge, MA, June 15, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters have exercised in full their over-allotment option to purchase 1,762,500 shares of common stock	Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters
Jun 13, 2005	Vertex Pharmaceuticals Announces Completion of Common Stock Offering Vertex Pharmaceuticals Announces Completion of Common Stock Offering Cambridge, MA, June 13, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of its public offering of 11,750,000 shares of common stock. The gross proceeds, before commissions and expenses, of	Vertex Pharmaceuticals Announces Completion of Common Stock Offering
Jun 10, 2005	Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702 Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702 Cambridge, MA, June 10, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of dosing in a Phase II clinical study in	Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702
Jun 09, 2005	Vertex Pharmaceuticals Announces Webcast of its Presentation at Goldman Sachs' Twenty-Sixth Annual Global Healthcare Conference Vertex Pharmaceuticals Announces Webcast of its Presentation at Goldman Sachs’ Twenty-Sixth Annual Global Healthcare Conference Cambridge, MA, June 9, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at Goldman Sachs' 26th Annual Global Healthcare	Vertex Pharmaceuticals Announces Webcast of its Presentation at Goldman Sachs' Twenty-Sixth Annual Global Healthcare Conference
Jun 07, 2005	Vertex Pharmaceuticals Announces Pricing of Common Stock Offering Vertex Pharmaceuticals Announces Pricing of Common Stock Offering Cambridge, MA, June 7, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the pricing of its public offering of 11,750,000 shares of its common stock at a price of $13.00 per share.	Vertex Pharmaceuticals Announces Pricing of Common Stock Offering
May 31, 2005	Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock Cambridge, MA, May 31, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced plans to offer 9,500,000 shares of its newly issued common stock in an underwritten public offering.	Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 17, 2005	Vertex Pharmaceuticals Reports that Oral Hepatitis C Protease Inhibitor, VX-950, Dramatically Reduces Viral Levels in Phase Ib Clinical Study -- Five Patients on 14-day Clinical Study Achieve Plasma Levels Below Limit of Quantitation --	Vertex Pharmaceuticals Reports that Oral Hepatitis C Protease Inhibitor, VX-950, Dramatically Reduces Viral Levels in Phase Ib Clinical Study
May 11, 2005	Shareholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting -- Eugene Cordes, Ph.D., Appointed to Vertex's Board of Directors --	Shareholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting
May 10, 2005	Vertex Pharmaceuticals Reports that VX-950, an Investigational Oral Hepatitis C Protease Inhibitor, Displays Potent Antiviral Activity in Early Clinical Study - Presentation of Study Results Planned at DDW -	Vertex Pharmaceuticals Reports that VX-950, an Investigational Oral Hepatitis C Protease Inhibitor, Displays Potent Antiviral Activity in Early Clinical Study